8-K filed Jun 11, 2026 at 08:02 ET
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage phase 1 (CB-011, anti-BCMA) trials at the EHA 2026 meeting. For vispa-cel in 2L LBCL (pivotal subgroup, N=27): 82% ORR, 67% CR, 17.1-month mPFS. For CB-011 in r/r MM (BCMA-naïve RDE cohort, N=12): 92% ORR, 83% CR, 91% MRD negativity. Both assets showed manageable safety profiles. The company also reiterated FDA alignment on the design of the ANTLER-3 pivotal phase 3 trial for vispa-cel. This data update is a notable but incremental catalyst for this pre-revenue clinical-stage biotech, positive efficacy readouts but from small, single-arm cohorts without financial guidance.